This document contains data obtained from January 1 through December 31, 2013 and is designed to assist the clinician in the selection of empiric antimicrobial therapy for initial infections.
University Health - Shreveport
Whenever possible, only the first isolate of a given species from an individual patient has been included for analysis. The Clinical
Antibiogram: January - December 2013
Microbiology Laboratory utilizes microdilution MIC testing as the primary method of susceptibility testing, and supplements, as
needed, with other methods such as disk diffusion and the E-test.
Interpretation of testing results – Susceptible (S), Intermediate (I),
or Resistant (R) – is based on guidelines developed by the Clinical
Laboratory Standards Institute (CLSI). Selection of antimicrobials
to be tested is made in collaboration with the pediatric and adult
Infectious Diseases faculties, the hospital Pharmacy Department,
and the Antibiotic Review Committee. The Clinical Microbiology
Laboratory can develop antibiograms for specific areas of the
medical center (e.g., specific floors, special care units, individual
clinics). Discuss your requests with Dr. Gerald Capraro, Director
of Clinical Microbiology (ext. 5-4611), or with Michelle Dillard-
Wayne, Manager of Clinical Microbiology (ext. 5-7846).
Key Aspects of the Antibiogram:
• Data are presented as % Susceptible.
• Out of a total of 592 In-Patient Staphylococcus aureus isolates,
• Out of a total of 179 Out-Patient Staphylococcus aureus isolates,
• For Staphylococcus species, susceptibility to oxacillin predicts
susceptibility to most cephalosporins, carbapenems, and β-
lactam/β-lactamase inhibitor combinations. Staphylococcus species demonstrating resistance to oxacillin are reported as
resistant to all penicillins, cephalosporins, carbapenems, and β-
lactam/β-lactamase inhibitor combinations.
• Enterococcus species are always resistant to aminoglycosides
(except high concentrations), cephalosporins, clindamycin, and
1 Total In-Patient and Out-Patient. Not identified to species level unless isolated from a normally sterile site.
• Out of a total of 673 Out-Patient Escherichia coli isolates, 80%
2 Rifampin should not be used as monotherapy due to the rapid development of resistance.
3 Staphylococcus species that are erythromycin-resistant & clindamycin-susceptible are tested for inducible clindamycin resistance prior to reporting.
• ESBL-producing organisms were observed in isolates of
4 Increasing resistance rate for clindamycin makes this antibiotic a less suitable second line agent for treatment of pneumococcal infections. Escherichia coli, Klebsiella pneumoniae, and Klebsiella oxytoca. These isolates were rare in 2013.
• Of the 63 Acinetobacter baumannii isolates in 2013, 49% were
• Yeast: 45 Candida isolates in 2013:
56% C. albicans (96% Susceptible to Fluconazole)
44% non-albicansCandida (40% Susceptible to Fluconazole)
University Health - Shreveport Antibiogram: January - December 2013 NEGATIVE gram 2013
88% of H . influenzae isolates were β-lactama se ne gative. Of the 12% that were β- lactamase- positive, all were susceptible to
ceftriaxone and trimethoprim- sulfamethoxazole.
ESLD Annual Scientific Meeting 2010 – PROGRAMME – 19th EADV CONGRESS GOTHENBURG 2010 SS06 / Room H2 European Society for Laser Dermatology (ESLD) Wednesday, 6th Oct 2010, 09:00 - 13:00 Theme of Course: How to improve Laser and Light Source Treatments in Dermatology – Theoretical and Practical Progress Learning Objectives Following this meeting the attendee will be able to: 1. Understand